How Fast Can You Lose Weight with Tirzepatide?

Last reviewed: June 9, 2026

Last updated: June 9, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Tirzepatide's weight reduction unfolds over months, not weeks, and the clearest single number in the labeling makes the pace explicit: in the Zepbound label's Study 4, 670 adults who completed a 36-week open-label treatment period had an average body weight loss of 20.9%, with mean body weight falling from 107.3 kg to 85.2 kg over that period. The pivotal efficacy trials measured their primary endpoint at week 72, not at week 12. Anyone promising a defined result by a defined week is describing marketing, not the evidence.

The Trials Were Designed Around 72 Weeks

Study 1 in the Zepbound label — the trial widely known as SURMOUNT-1 — was a 72-week randomized, double-blind, placebo-controlled trial in 2,539 adults with obesity, or overweight plus at least one weight-related comorbid condition, excluding people with type 2 diabetes. Mean percent change in body weight at week 72 was −15.0% at 5 mg, −19.5% at 10 mg and −20.9% at 15 mg, versus −3.1% with placebo.

The design itself tells you about pace. Dosages were escalated over a period of up to 20 weeks before the maintenance period began, and weight reduction was assessed after 72 weeks of treatment with at least 52 weeks at the maintenance dose. Roughly the first five months of the trial were spent reaching the dose the results are attributed to.

A Real 36-Week Anchor

Study 4 gives the most useful mid-course data point in the label because it reports a single number for a defined interval. All 783 enrolled patients received open-label tirzepatide for 36 weeks with escalation over up to 20 weeks to a maximum tolerated dosage of 10 mg or 15 mg. Of the 670 who reached randomization at week 36, 93% were at 15 mg weekly and 7% at 10 mg, and the average body weight loss from week 0 to week 36 was 20.9%.

Two caveats keep that figure honest. It describes people who stayed on treatment — 14.4% discontinued before week 36, with adverse events the most common reason at 6.8%. And it is a mean: half the group did better and half did worse, sometimes considerably.

Averages Hide Enormous Variation

The responder analysis in Study 1 is more informative than the mean for anyone trying to set expectations. At week 72, the proportion losing at least 5% of body weight was 85.1%, 88.9% and 90.9% at 5 mg, 10 mg and 15 mg versus 34.5% on placebo. At the 10% threshold the figures were 68.5%, 78.1% and 83.5% versus 18.8%. At 15%: 48.0%, 66.6% and 70.6% versus 8.8%. At 20%: 30.0%, 50.1% and 56.7% versus 3.1%.

Read the top row against the bottom row. On the highest dosage, more than nine in ten people lost at least 5% — but only a little over half lost 20% or more, and roughly one in ten did not reach 5%. The same drug, the same protocol, the same duration, and a very wide spread of outcomes.

Diabetes Changes the Numbers

Study 2 enrolled 938 adults with a BMI of 27 kg/m² or greater and type 2 diabetes, with HbA1c between 7 and 10%, over the same 72 weeks. Mean percent change in body weight was −12.8% at 10 mg and −14.7% at 15 mg versus −3.2% with placebo — meaningful, but consistently smaller than in the population without diabetes.

That gap appears across this drug class and is worth knowing in advance, because someone with type 2 diabetes comparing their trajectory against headline figures from a trial that excluded diabetes is measuring themselves against the wrong benchmark.

Why the Early Weeks Feel Slow — and Why That Is the Design

Tirzepatide starts at 2.5 mg; there is no lower strength, and 0.25 mg is a semaglutide starting dose rather than a tirzepatide one. In the trials, dosages were increased in 2.5 mg increments over a period of up to 20 weeks to reach the assigned maintenance dose, a schedule intended to limit gastrointestinal adverse reactions. Early weeks are therefore spent at doses below the ones the published results reflect.

There is a pharmacological reason the first weeks can feel different in another way too: the Zepbound label notes that tirzepatide delays gastric emptying, that the delay is largest after the first dose, and that this effect diminishes over time. A strong initial response is not a forecast of the eventual total, and a modest one is not a verdict. Where you sit in an escalation schedule, and what dose is appropriate for you at all, are decisions for your prescriber and are governed by the pharmacy label that comes with your medication.

Stopping Reverses the Trajectory

Study 4 continued past week 36 as a randomized withdrawal trial: after the open-label period, 670 patients were randomized to continue tirzepatide or switch to placebo for 52 weeks, out to week 88. Continued treatment produced a statistically significant reduction in body weight compared with placebo over that interval, while the group that stopped regained weight.

The practical reading is that speed matters less than durability. A rapid early loss that is not sustained is worth less than a slower one that holds, and the question worth asking a prescriber at month three is not "am I losing fast enough" but "is this trajectory one I can stay on."

One Brand Distinction Worth Getting Right

All of the weight-reduction data above come from Zepbound, the tirzepatide product approved for chronic weight management and for moderate to severe obstructive sleep apnea in adults with obesity. Mounjaro contains the same molecule but is approved only for glycemic control in type 2 diabetes; weight change was measured in its diabetes program but is not what its approval rests on.

Compounded tirzepatide is a third category. It is not an FDA-approved finished product, the FDA does not review compounded drugs for safety, effectiveness or quality before marketing, and it is not a generic version of either brand — no approved generic tirzepatide exists.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How much weight is lost on tirzepatide at 36 weeks?

In the Zepbound label's Study 4, the 670 patients who completed a 36-week open-label treatment period had an average body weight loss of 20.9%, with mean body weight falling from 107.3 kg at week 0 to 85.2 kg at week 36. At that point 93% were at a maximum tolerated dosage of 15 mg weekly. Note that 14.4% of enrolled patients discontinued before week 36, most commonly because of adverse events.

What did the 72-week trials show?

Study 1 enrolled 2,539 adults with obesity or overweight plus a weight-related condition, excluding type 2 diabetes. Mean percent change in body weight at week 72 was −15.0% at 5 mg, −19.5% at 10 mg and −20.9% at 15 mg, versus −3.1% with placebo. Study 2, in 938 adults with type 2 diabetes and a BMI of 27 or greater, reported −12.8% at 10 mg and −14.7% at 15 mg versus −3.2%.

Why is weight loss slower in the first couple of months?

Because the trials spent that period escalating the dose. Dosages were increased in 2.5 mg increments over a period of up to 20 weeks to reach the assigned maintenance dose, a schedule intended to limit gastrointestinal adverse reactions, and results are reported after at least 52 weeks at maintenance. The label also notes that the delay in gastric emptying is largest after the first dose and diminishes over time.

Does everyone lose about 20%?

No, the spread is wide. In Study 1 at the 15 mg dosage, 90.9% of patients lost at least 5% of body weight, 83.5% lost at least 10%, 70.6% lost at least 15%, and 56.7% lost at least 20%. So roughly one in ten did not reach the 5% threshold, and a little under half did not reach 20%. Mean results describe a population, not an individual trajectory.

What happens if tirzepatide is stopped?

Weight regain is the documented pattern. Study 4 randomized patients at week 36 either to continue tirzepatide or switch to placebo for 52 more weeks. Continued treatment produced a statistically significant reduction in body weight compared with placebo through week 88, while the group switched to placebo regained weight. Any decision about continuing, pausing or stopping belongs with your prescriber.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.